vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and IMPINJ INC (PI). Click either name above to swap in a different company.

IMPINJ INC is the larger business by last-quarter revenue ($74.3M vs $38.3M, roughly 1.9× ImmunityBio, Inc.). IMPINJ INC runs the higher net margin — 11.2% vs -161.8%, a 173.0% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -0.0%). IMPINJ INC produced more free cash flow last quarter ($2.2M vs $-71.3M).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Impinj, Inc. is an American manufacturer of radio-frequency identification (RFID) devices and software. The company was founded in 2000 and is headquartered in Seattle, Washington. The company was started based on the research done at the California Institute of Technology by Carver Mead and Chris Diorio. Impinj currently produces EPC Class 1, Gen 2 passive UHF RFID chips, RFID readers, RFID reader chips, and RFID antennas, and software applications for encoding chips, and gathering business ...

IBRX vs PI — Head-to-Head

Bigger by revenue
PI
PI
1.9× larger
PI
$74.3M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+407.0% gap
IBRX
407.0%
-0.0%
PI
Higher net margin
PI
PI
173.0% more per $
PI
11.2%
-161.8%
IBRX
More free cash flow
PI
PI
$73.5M more FCF
PI
$2.2M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IBRX
IBRX
PI
PI
Revenue
$38.3M
$74.3M
Net Profit
$-61.9M
$8.3M
Gross Margin
99.0%
49.1%
Operating Margin
-169.0%
30.5%
Net Margin
-161.8%
11.2%
Revenue YoY
407.0%
-0.0%
Net Profit YoY
-4.7%
EPS (diluted)
$-0.06
$0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
PI
PI
Q1 26
$74.3M
Q4 25
$38.3M
$92.8M
Q3 25
$32.1M
$96.1M
Q2 25
$26.4M
$97.9M
Q1 25
$16.5M
$74.3M
Q4 24
$7.6M
$91.6M
Q3 24
$6.1M
$95.2M
Q2 24
$102.5M
Net Profit
IBRX
IBRX
PI
PI
Q1 26
$8.3M
Q4 25
$-61.9M
$-1.1M
Q3 25
$-67.3M
$-12.8M
Q2 25
$-92.6M
$11.6M
Q1 25
$-129.6M
$-8.5M
Q4 24
$-59.2M
$-2.7M
Q3 24
$-85.7M
$221.0K
Q2 24
$10.0M
Gross Margin
IBRX
IBRX
PI
PI
Q1 26
49.1%
Q4 25
99.0%
51.8%
Q3 25
99.4%
50.3%
Q2 25
99.5%
57.8%
Q1 25
99.6%
49.4%
Q4 24
50.5%
Q3 24
50.0%
Q2 24
56.1%
Operating Margin
IBRX
IBRX
PI
PI
Q1 26
30.5%
Q4 25
-169.0%
-2.9%
Q3 25
-173.5%
0.7%
Q2 25
-269.8%
11.1%
Q1 25
-390.1%
-12.9%
Q4 24
-919.0%
-3.9%
Q3 24
-1314.3%
-0.8%
Q2 24
8.8%
Net Margin
IBRX
IBRX
PI
PI
Q1 26
11.2%
Q4 25
-161.8%
-1.2%
Q3 25
-209.8%
-13.3%
Q2 25
-350.3%
11.8%
Q1 25
-784.9%
-11.4%
Q4 24
-783.4%
-2.9%
Q3 24
-1404.0%
0.2%
Q2 24
9.7%
EPS (diluted)
IBRX
IBRX
PI
PI
Q1 26
$0.14
Q4 25
$-0.06
$-0.02
Q3 25
$-0.07
$-0.44
Q2 25
$-0.10
$0.39
Q1 25
$-0.15
$-0.30
Q4 24
$-0.08
$-0.06
Q3 24
$-0.14
$0.01
Q2 24
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
PI
PI
Cash + ST InvestmentsLiquidity on hand
$242.8M
$131.8M
Total DebtLower is stronger
$241.5M
Stockholders' EquityBook value
$-500.5M
Total Assets
$501.9M
$502.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
PI
PI
Q1 26
$131.8M
Q4 25
$242.8M
$175.3M
Q3 25
$257.8M
$190.1M
Q2 25
$153.7M
$193.2M
Q1 25
$61.6M
$147.9M
Q4 24
$149.8M
$164.7M
Q3 24
$130.4M
$170.3M
Q2 24
$220.2M
Total Debt
IBRX
IBRX
PI
PI
Q1 26
$241.5M
Q4 25
$280.9M
Q3 25
$280.4M
Q2 25
Q1 25
Q4 24
$283.5M
Q3 24
Q2 24
Stockholders' Equity
IBRX
IBRX
PI
PI
Q1 26
Q4 25
$-500.5M
$209.2M
Q3 25
$-524.3M
$195.0M
Q2 25
$-570.7M
$187.7M
Q1 25
$-591.4M
$160.6M
Q4 24
$-489.1M
$149.9M
Q3 24
$-745.1M
$136.1M
Q2 24
$117.0M
Total Assets
IBRX
IBRX
PI
PI
Q1 26
$502.5M
Q4 25
$501.9M
$545.2M
Q3 25
$519.0M
$516.5M
Q2 25
$402.1M
$508.8M
Q1 25
$303.8M
$479.8M
Q4 24
$382.9M
$489.1M
Q3 24
$364.6M
$476.4M
Q2 24
$446.1M
Debt / Equity
IBRX
IBRX
PI
PI
Q1 26
Q4 25
1.34×
Q3 25
1.44×
Q2 25
Q1 25
Q4 24
1.89×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
PI
PI
Operating Cash FlowLast quarter
$-70.4M
Free Cash FlowOCF − Capex
$-71.3M
$2.2M
FCF MarginFCF / Revenue
-186.2%
3.0%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M
$61.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
PI
PI
Q1 26
Q4 25
$-70.4M
$15.1M
Q3 25
$-68.9M
$20.9M
Q2 25
$-79.7M
$33.9M
Q1 25
$-85.9M
$-11.1M
Q4 24
$-85.1M
$12.6M
Q3 24
$-98.8M
$10.1M
Q2 24
$45.5M
Free Cash Flow
IBRX
IBRX
PI
PI
Q1 26
$2.2M
Q4 25
$-71.3M
$13.6M
Q3 25
$-69.6M
$18.0M
Q2 25
$-80.8M
$27.3M
Q1 25
$-87.0M
$-13.0M
Q4 24
$-87.3M
$8.5M
Q3 24
$-101.6M
$4.7M
Q2 24
$44.1M
FCF Margin
IBRX
IBRX
PI
PI
Q1 26
3.0%
Q4 25
-186.2%
14.7%
Q3 25
-217.2%
18.7%
Q2 25
-305.9%
27.9%
Q1 25
-526.9%
-17.5%
Q4 24
-1155.4%
9.3%
Q3 24
-1663.2%
4.9%
Q2 24
43.0%
Capex Intensity
IBRX
IBRX
PI
PI
Q1 26
Q4 25
2.4%
1.6%
Q3 25
2.3%
3.1%
Q2 25
4.1%
6.7%
Q1 25
6.8%
2.5%
Q4 24
28.0%
4.5%
Q3 24
45.7%
5.7%
Q2 24
1.3%
Cash Conversion
IBRX
IBRX
PI
PI
Q1 26
Q4 25
Q3 25
Q2 25
2.93×
Q1 25
Q4 24
Q3 24
45.56×
Q2 24
4.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons